Form 4: Keros Therapeutics Director Sells Shares in Tender Offer

Keros Therapeutics Director Carl L. Gordon disposed of 214,522 shares of common stock at $17.75 per share in connection with a cash tender offer.

Summary

• Carl L. Gordon, a Director and 10% Owner of Keros Therapeutics, Inc., reported the disposal of common stock.
• The transactions occurred on November 21, 2025.
• A total of 214,522 shares of common stock were disposed of.
• The shares were sold at a price of $17.75 per share.
• The disposal was made in connection with the Issuer's completion of a cash tender offer.
• Following these transactions, Carl L. Gordon indirectly beneficially owns 759,155 shares through OrbiMed Private Investments VII, LP and 45,057 shares through OrbiMed Genesis Master Fund, L.P.
• Carl L. Gordon disclaims beneficial ownership of these indirectly held securities except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a disposal by a director, which could be seen negatively, but it is explicitly linked to a tender offer, which is a corporate action. Without more context on the tender offer, it is hard to assign a strong positive or negative sentiment.

Positives

• The disposal was part of a cash tender offer, which can indicate a strategic move by the company or a liquidity event for shareholders.

Negatives

• A significant disposal of shares by a director and 10% owner could be perceived negatively by the market, potentially signaling a lack of confidence, although in this case, it is tied to a tender offer.

Risks

• The market might interpret the director's sale as a negative signal, potentially impacting investor sentiment.
• The tender offer itself, while providing liquidity, might have implications for the company's capital structure or ownership concentration.

Future Outlook

The filing does not contain specific forward-looking statements or guidance, beyond the reporting of past transactions.

Management Comments

• Each of the Reporting Person, OrbiMed Advisors, OrbiMed GP, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), except to the extent of his or its pecuniary interest therein, if any.
• This report shall not be deemed an an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Industry Context

This Form 4 filing reports an insider transaction related to a cash tender offer, which is a common mechanism for companies to repurchase shares or for large shareholders to exit positions. The specific implications depend on the details of Keros Therapeutics' tender offer, which are not fully disclosed in this Form 4.

Stakeholder Impact

• Shareholders: Those who participated in the tender offer received cash for their shares. The disposal by a director might influence market perception.

Next Steps

• The filing does not mention any specific future actions or milestones for the company or the reporting person, beyond the completion of the tender offer.

Key Dates

Recommendation

The filing reports a significant disposal of shares by a director and 10% owner, Carl L. Gordon, in connection with a cash tender offer. While insider selling can sometimes signal a lack of confidence, the context of a tender offer suggests a corporate event rather than a discretionary sale based on new negative information. Without further details on the tender offer's rationale, its impact on the company's capital structure, and Keros Therapeutics' overall financial health and strategic outlook, a definitive 'buy' or 'sell' recommendation is premature. Investors should 'hold' and seek additional information regarding the tender offer and the company's fundamentals.

Keywords

Keros Therapeutics, KROS, SEC Form 4, Insider Trading, Director Share Sale, Tender Offer, Beneficial Ownership, OrbiMed